BIRC5 is a Prognostic Biomarker Associated with Tumor Immune Cell Infiltration

Overview

Journal Sci Rep

Specialty Science

Date 2021 Jan 12

PMID 33431968

Citations 38

Authors

Linlong Xu

Wenpeng Yu

Han Xiao

Kang Lin

Affiliations

Soon will be listed here.

Abstract

BIRC5 is an immune-related gene that inhibits apoptosis and promotes cell proliferation. It is highly expressed in most tumors and leads to poor prognosis in cancer patients. This study aimed to analyze the relationship between the expression level of BIRC5 in different tumors and patient prognosis, clinical parameters, and its role in tumor immunity. Genes co-expressed with BIRC5 were analyzed, and functional enrichment analysis was performed. The relationship between BIRC5 expression and the immune and stromal scores of tumors in pan-cancer patients and the infiltration level of 22 tumor-infiltrating lymphocytes (TILs) was analyzed. The correlation of BIRC5 with immune checkpoints was conducted. Functional enrichment analysis showed that genes co-expressed with BIRC5 were significantly associated with the mitotic cell cycle, APC/C-mediated degradation of cell cycle proteins, mitotic metaphase, and anaphase pathways. Besides, the high expression of BIRC5 was significantly correlated with the expression levels of various DNA methyltransferases, indicating that BIRC5 regulates DNA methylation. We also found that BIRC5 was significantly correlated with multiple immune cells infiltrates in a variety of tumors. This study lays the foundation for future research on how BIRC5 modulates tumor immune cells, which may lead to the development of more effective targeted tumor immunotherapies.

Citing Articles

Interpretable single-cell factor decomposition using sciRED.

Pouyabahar D, Andrews T, Bader G Nat Commun. 2025; 16(1):1878.

PMID: 39987196 PMC: 11846867. DOI: 10.1038/s41467-025-57157-2.

The functional correlation between mir-16-5p and BIRC5 gene in colorectal cancer: integrated analysis of transcriptomics and in vitro validation.

Aslan E, Yavas C, Akcali N, Eslamkhah S, Meral G, Batur L Mol Biol Rep. 2025; 52(1):252.

PMID: 39976834 DOI: 10.1007/s11033-025-10355-z.

BIRC5 as a prognostic and diagnostic biomarker in pan-cancer: an integrated analysis of expression, immune subtypes, and functional networks.

Li G, Wang Y, Wang W, Lv G, Li X, Wang J Front Genet. 2024; 15:1509342.

PMID: 39703228 PMC: 11655497. DOI: 10.3389/fgene.2024.1509342.

Doxorubicin resistance involves modulation of interferon signaling, transcriptional bursting, and gene co-expression patterns of U-ISGF3-related genes.

Trzaskoma P, Jung S, Kanno Y, OShea J, Chow C Neoplasia. 2024; 58:101071.

PMID: 39405604 PMC: 11574522. DOI: 10.1016/j.neo.2024.101071.

Interpretable single-cell factor decomposition using sciRED.

Pouyabahar D, Andrews T, Bader G Res Sq. 2024; .

PMID: 39149508 PMC: 11326389. DOI: 10.21203/rs.3.rs-4819117/v1.

References

Andersen M, Marie Svane I, Becker J, Straten P . The universal character of the tumor-associated antigen survivin. Clin Cancer Res. 2007; 13(20):5991-4. DOI: 10.1158/1078-0432.CCR-07-0686. View

Gotwals P, Cameron S, Cipolletta D, Cremasco V, Crystal A, Hewes B . Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017; 17(5):286-301. DOI: 10.1038/nrc.2017.17. View

Hervouet E, Vallette F, Cartron P . Impact of the DNA methyltransferases expression on the methylation status of apoptosis-associated genes in glioblastoma multiforme. Cell Death Dis. 2011; 1:e8. PMC: 3032516. DOI: 10.1038/cddis.2009.7. View

Miller K, Nogueira L, Mariotto A, Rowland J, Yabroff K, Alfano C . Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69(5):363-385. DOI: 10.3322/caac.21565. View

Boidot R, Vegran F, Jacob D, Chevrier S, Gangneux N, Taboureau J . The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. Genes Chromosomes Cancer. 2008; 47(4):299-308. DOI: 10.1002/gcc.20533. View

Budczies J, Bockmayr M, Denkert C, Klauschen F, Lennerz J, Gyorffy B . Classical pathology and mutational load of breast cancer - integration of two worlds. J Pathol Clin Res. 2016; 1(4):225-38. PMC: 4939893. DOI: 10.1002/cjp2.25. View

Szklarczyk D, Gable A, Lyon D, Junge A, Wyder S, Huerta-Cepas J . STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2018; 47(D1):D607-D613. PMC: 6323986. DOI: 10.1093/nar/gky1131. View

Lyko F . The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2017; 19(2):81-92. DOI: 10.1038/nrg.2017.80. View

Li F . Survivin study: what is the next wave?. J Cell Physiol. 2003; 197(1):8-29. DOI: 10.1002/jcp.10327. View

10.

Newman A, Steen C, Liu C, Gentles A, Chaudhuri A, Scherer F . Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019; 37(7):773-782. PMC: 6610714. DOI: 10.1038/s41587-019-0114-2. View

11.

Berinstein N, Karkada M, Oza A, Odunsi K, Villella J, Nemunaitis J . Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients. Oncoimmunology. 2015; 4(8):e1026529. PMC: 4570133. DOI: 10.1080/2162402X.2015.1026529. View

12.

Zhang Q, Li H, Mao Y, Wang X, Zhang X, Yu X . Apoptotic SKOV3 cells stimulate M0 macrophages to differentiate into M2 macrophages and promote the proliferation and migration of ovarian cancer cells by activating the ERK signaling pathway. Int J Mol Med. 2019; 45(1):10-22. PMC: 6889918. DOI: 10.3892/ijmm.2019.4408. View

13.

Steinbakk A, Malpica A, Slewa A, Skaland I, Gudlaugsson E, Janssen E . Biomarkers and microsatellite instability analysis of curettings can predict the behavior of FIGO stage I endometrial endometrioid adenocarcinoma. Mod Pathol. 2011; 24(9):1262-71. DOI: 10.1038/modpathol.2011.75. View

14.

Smallwood A, Esteve P, Pradhan S, Carey M . Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev. 2007; 21(10):1169-78. PMC: 1865489. DOI: 10.1101/gad.1536807. View

15.

Colnaghi R, Wheatley S . Liaisons between survivin and Plk1 during cell division and cell death. J Biol Chem. 2010; 285(29):22592-604. PMC: 2903399. DOI: 10.1074/jbc.M109.065003. View

16.

Ma A, Lu J, Zhou X, Wang Y . Histone deacetylation directs DNA methylation in survivin gene silencing. Biochem Biophys Res Commun. 2010; 404(1):268-72. DOI: 10.1016/j.bbrc.2010.11.105. View

17.

Mita A, Mita M, Nawrocki S, Giles F . Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008; 14(16):5000-5. DOI: 10.1158/1078-0432.CCR-08-0746. View

18.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

19.

Li F, Ambrosini G, Chu E, Plescia J, Tognin S, Marchisio P . Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998; 396(6711):580-4. DOI: 10.1038/25141. View

20.

Duffy M, ODonovan N, Brennan D, Gallagher W, Ryan B . Survivin: a promising tumor biomarker. Cancer Lett. 2007; 249(1):49-60. DOI: 10.1016/j.canlet.2006.12.020. View